ONKURE THERAPEUTICS, INC.: operating cash flow
Operating cash flow for ONKURE THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ONKURE THERAPEUTICS, INC. financial histories
What this measure means
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
Exact concept: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | -51,828,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104147 |
| 2024-01-01 | 2024-12-31 | -51,117,000 | USD | 2026-03-12 | 10-K · 0001193125-26-104147 |
| 2023-01-01 | 2023-12-31 | -34,546,000 | USD | 2025-03-10 | 10-K · 0000950170-25-036252 |
| 2022-01-01 | 2022-12-31 | -47,362,000 | USD | 2024-03-28 | 10-K · 0000950170-24-038009 |
| 2021-01-01 | 2021-12-31 | -37,983,000 | USD | 2023-03-27 | 10-K · 0000950170-23-009978 |
| 2020-01-01 | 2020-12-31 | -18,536,000 | USD | 2022-03-23 | 10-K · 0001558370-22-004158 |
Related financial histories
- ONKURE THERAPEUTICS, INC.: total assets
- ONKURE THERAPEUTICS, INC.: total liabilities
- ONKURE THERAPEUTICS, INC.: stockholders equity
- ONKURE THERAPEUTICS, INC.: cash and cash equivalents
- ONKURE THERAPEUTICS, INC.: net income or loss
- ONKURE THERAPEUTICS, INC.: capital expenditure payments
- ONKURE THERAPEUTICS, INC.: financing cash flow
- ONKURE THERAPEUTICS, INC.: investing cash flow
- ONKURE THERAPEUTICS, INC.: retained earnings or deficit
- ONKURE THERAPEUTICS, INC.: basic weighted-average shares
- ONKURE THERAPEUTICS, INC.: diluted weighted-average shares
- ONKURE THERAPEUTICS, INC.: basic earnings per share
- ONKURE THERAPEUTICS, INC.: diluted earnings per share
- ONKURE THERAPEUTICS, INC.: net property, plant and equipment
- ONKURE THERAPEUTICS, INC.: share-based compensation expense
- ONKURE THERAPEUTICS, INC.: operating income or loss
- ONKURE THERAPEUTICS, INC.: current assets
- ONKURE THERAPEUTICS, INC.: current liabilities
- ONKURE THERAPEUTICS, INC.: current accounts payable
- ONKURE THERAPEUTICS, INC.: operating expenses
- ONKURE THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- ONKURE THERAPEUTICS, INC. / CIK 0001637715
- Captured
- 2026-09-21T17:21:25.655Z
- SEC response SHA-256
ab599239a09de00af4c364ae8d2efaacdab40a29b1c6a3d8520289f7fad75481
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001637715.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))